Skip to main content
NCBI home page
Journal of Ophthalmic & Vision Research logoLink to Journal of Ophthalmic & Vision Research
. 2021 Oct 25;16(4):552–557. doi: 10.18502/jovr.v16i4.9744

Amniotic Membrane Transplantation for Persistent Epithelial Defects and Ulceration due to Pseudomonas Keratitis in a Rabbit Model

Mohammad Mehdi Soltan Dallal 1,2, Farhad Nikkhahi 3, Seyed Mostafa Imeni 4, Saber Molaei 5, Seyed Kazem Hosseini 6, Zohreh Kalafi 2, Sara Sharifi Yazdi 7, Hedroosha Molla Agha Mirzaei 8
PMCID: PMC8593546  PMID: 34840677

Abstract

Purpose

The use of amniotic membrane has been suggested in the treatment of infectious keratitis for its intrinsic anti-infective properties probably mediated by its anti-inflammatory effects. The aim of this study was to investigate the effect of amniotic membrane transplantation (AMT) along with ciprofloxacin to cure the primary stages of Pseudomonas keratitis.

Methods

In total, 28 rabbits were selected and divided in four groups as follows: group 1 as control, group 2 with amniotic membrane, group 3 with ciprofloxacin, and group 4 with amniotic membrane combined with ciprofloxacin. About 0.05 cc suspension of Pseudomonas aeruginosa, 27853 ATCC was injected into corneal stroma.

Results

The results showed groups of AMT, AMT + ciprofloxacin, and ciprofloxacin had 0% perforation while the control group had 85.6%. Average infiltration of 5.5 mm was observed in ciprofloxacin group, 5 mm in AMT + ciprofloxacin group, 24 mm in AMT group, and finally 23.75 mm for control. Amniotic membrane showed to be effective in prevention of cornea perforation as well as remission of Pseudomonas keratitis. There was no significant difference between ciprofloxacin groups in comparison with ciprofloxacin + AMT group. However, regarding the anti-inflammatory effect, the process of improvement of inflammation in ciprofloxacin + AMT group was faster.

Conclusion

Transplantation of amniotic membrane in the primary stages of Pseudomonas keratitis treatment remarkably prevents the disease and it can be used to control its process.

Keywords: Ciprofloxacin, Human Amniotic Membrane, Keratitis, Pseudomonas aeruginosa, Rabbit

INTRODUCTION

Human amniotic membrane (AM) forms the inner wall of the membranous sac that surrounds and protects the embryo during gestation. It consists of a single layer of ectodermally derived columnar epithelial cells attached to a basement membrane with an underlying layer of mesenchyme.[1] Amniotic membrane transplantation (AMT) is widely used in various ocular surface diseases such as neurotrophic keratitis and persistent epithelial defects,[2,3] band keratopathy,[4] bullous keratopathy,[5,6] after excimer laser photorefractive keratectomy,[7,8] after the excision of a conjunctival mass,[9,10] pterygium,[11,12] ocular surface reconstruction in symblepharon,[13,14] acute chemical injury,[15,16] and a chronic limbal deficiency.[17,18] When used as a graft (epithelial side up), AM is expected to become incorporated in the recipient tissue. If it is used as a patch (epithelial side down), it works as a biological bandage affording a cover for a limited duration or a combination of these. The use of AM has been also suggested in the treatment of infectious keratitis because of its intrinsic anti-infective properties probably mediated by its anti-inflammatory effects and because AM may act as a long-term drug delivery system.[19,20,21] The antimicrobial effects of AM have been demonstrated against several species such as Escherichia coli, Group A Streptococci, Pseudomonas aeruginosa, and Staphylococcus aureus.[22,23] AM graft for epithelial reformation has been employed in order to eradicate the P. aeruginosa infection of keratitis and have exhibited desirable outcomes.[24]

The aim of the current study was to investigate the effect of AMT along with ciprofloxacin to cure the primary stages of Pseudomonas keratitis.

METHODS

All experiments were carried out in accordance with the UK Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments. In addition, this study is certified by accreditation research ethics national committee with issue code of IR.TUMS.REC.1394.2091.

In total, 28 male rabbits with an average weight of 1.5–2 kg were selected. The AM was prepared according to Song and Kim method.[25] Human placenta was obtained after an elective caesarean section in a woman who was seronegative for human immunodeficiency virus, hepatitis B, C, and syphilis. Under a lamellar flow hood, the placenta was first washed free of blood clots with sterile saline. The inner AM was separated from the rest of the chorine by blunt dissection and flattened onto a nitrocellulose membrane.[26] The membrane with the filter was then washed three times with phosphate buffered saline (PBS) containing 50 μg/ml penicillin, 50 μg/ml streptomycin, and 2.5 μg/ml amphotericin B and put in M199 culture for 24 hr with antibiotic solution including streptomycin, cloxacillin, ceftriaxone, and amphotericin B, and finally packed in pieces of 1.5 × 1.5 in three of sterilized nylon and stored in –80ºC in freezer. Twenty-eight rabbits were divided into four groups as follows: group 1 as control group [Figure 1A], group 2 as AM [Figure 1-B], group 3 as ciprofloxacin [Figure 1C], and group 4 as AM combined with ciprofloxacin [Figure 1D].

The rabbits were anesthetized with intramuscular injection of ketamine hydrochloride (30 mg/kg) and xylazine hydrochloride (5 mg/kg) and then a drop of tetracaine HCL 0.5% was applied to the rabbits' right eye. About 0.05 cc suspension of P. aeruginosa 27853 ATCC was injected into corneal stroma with a sterile 30 G needle connected to a micro-syringe, using an operating microscope. The experimental keratitis was allowed to proceed untreated for 20 hr. There was no interference in the control group. In groups 3 and 4, the AM in pieces of 1.5 × 1.5 cm transplanted to the entire corneal surface by eight interrupted 10.0 nylon sutures. On the first day, ciprofloxacin drop was injected to groups 2 and 4 every 30 min.

On the second day to seventh day every 2 hr, the results were registered in aspect of perforation in cornea and the amount of infiltration by the use of image J 1 software.

Figure 1.

Figure 1

Open in a new tab

Cornea infiltration of the four groups of experiment. (A: Control group; B: AMT group; C: ciprofloxacin; D: AMT + ciprofloxacin).

RESULTS

Results were registered as clinical reports on the first, third, and seventh day [Table 1]. During the first 20 hr, after injecting P. aeruginosa, a white opacity appeared in all rabbits. Rabbits had corneal ulcers and on the second day, the conjunctiva was markedly hyperemic in four groups. At the end of the first week, Hypopyon formation was noticed in five eyes in the AMT group. Corneal perforation was noticed in four cases in the control group but in no case in other groups.

Table 1.

Clinical results of four groups on the first, third, and seventh day and in the first 20 hr*

Groups/days First day Third day Seventh day
Control Average infiltration 2.25 mm with corneal opacity and without epithelial defect Average infiltration 7.01 mm with corneal opacity, epithelial defect, and descemeto cell Average infiltration 23.75 mm with corneal opacity and epithelial defect
AMT Average infiltration 2.62 mm and without epithelial defect Average infiltration 6.25 mm and without epithelial defect Average infiltration 24 mm and without epithelial defect, melting, and scar
ciprofloxacin Average infiltration 2.35 mm and without epithelial defect Average infiltration 4.51 mm and epithelial defect Average infiltration 5.5 mm, epithelial defect, and scar with diameter 2.5 × 2.5 mm
ciprofloxacin + AMT Average infiltration 2.6 mm and without epithelial defect Average infiltration 4 mm and without epithelial defect Average infiltration 5 mm and without epithelial defect and scar
*Findings in the first 20 hours only the first day for all groups **AMT, amniotic membrane transplantation
Open in a new tab

Table 2.

Clinical outcomes of perforation and infiltration in all four groups of Pseudomonas keratitis

Results AMT* AMT + ciprofloxacin ciprofloxacin Control
Perforation (0%) 0 (0%) 0 (0%) 0 (85.7%) 6
Infiltration 24 mm 5 mm 5.5 mm 23.75 mm
Significant difference compared to control group (P-value) P < 0.5 P < 0.5 P < 0.5 –
*AMT, amniotic membrane transplantation
Open in a new tab

The results showed that the cornea had infiltration in which central part, an area with the size of 6 mm had descemeto cell and progress toward causing perforation in cornea control group (A: Control group). On the other hand, AMT group conjunctiva inflammation showed to be less than control group and in cornea examination the amount of infiltration showed to be 24 mm (B: AMT group). For ciprofloxacin group, ciprofloxacin sediment was clearly visible (C: ciprofloxacin) and finally in the group with ciprofloxacin + AMT as well as the ciprofloxacin group the decrease of opacity cornea was quite visible (D: AMT + ciprofloxacin).

The clinical results of four groups in examination of Pseudomonas keratitis are also shown in Table 2. These results showed that AMT + ciprofloxacin group had 0% perforation and the control group had 85.7%. Average infiltrations were 5 mm in AMT + ciprofloxacin groups and 23.75 mm in control.

The result showed that the AMT, ciprofloxacin, and AMT + ciprofloxacin were effective on perforation and infiltration on all groups compared to the control group.

In addition, there was no significant difference between ciprofloxacin group and ciprofloxacin combination with AM. In the same way, there was no significant difference between membrane amniotic group and ciprofloxacin compared with combined group of ciprofloxacin with membrane amniotic.

DISCUSSION

Few studies have investigated the effect of AMT in the surgical treatment of severe infectious keratitis with corneal ulceration or perforation.[19,23,27] The main advantages of AMT in the treatment of bacterial keratitis that we observed are the epithelial bandage properties, which allowed early use of topical steroids; the anti-inflammatory and anti-scarring effects of the AM, the promotion of epithelialization, and the possible benefits of a direct antimicrobial role of the AM.[28] These studies found AMT to be effective in treating neurotrophic ulcer, inflammatory corneal ulcer, bullous keratopathy, inflammatory or non-inflammatory scleral ulcer and as an adjuvant treatment of pterygium excision. The basement membrane of an AM promotes epithelial growth and differentiation, reinforces the adhesion of basal epithelial cells and prevents epithelial apoptosis. The stroma matrix suppresses TGF-b signaling, proliferation, and myofibroblastic differentiation of normal human corneal and limbal fibroblasts and thus, inhibiting the unwanted production of extracellular matrix and scarring.[6] These properties have made the AM an ideal reconstructive substrate for repairing persistent epithelial defects and corneal ulcers,[2] conjunctival defect,[9,10] chemical or thermal injury,[15,29] and limbal cell deficiency.[16,17] The application of AM in the treatment of corneal perforation and scleromalacia has been also reported.[30,31] The human AM possesses anti-inflammatory, antifibrotic, and antiangiogenic properties, and these attributes make it ideal for ocular surface reconstruction procedures.[32,33] In addition, the AM also has antimicrobial properties due partly to its anti-inflammatory effects, and also due to secretion of elfin and secretory leucocyte proteinase inhibitor, both of which have antimicrobial actions and act as components of the innate immune system.[34,35] It also contains cystatin E, an analogue of cysteine proteinase inhibitors, which has complementary antiviral properties.[36] Furthermore, AM transplantation (AMT) is reserved for cases of postinfectious ulcers after an appropriate period of anti-infective treatment when clinical signs are improving.[37] This is because the anti-infective properties of AM are nonspecific and not considered to be potent enough to be effective in acute infective keratitis. This is the reason behind the concept of fortifying AM with antimicrobial drugs to make it a viable therapeutic modality in the setting of active infections of the cornea. Antibiotic-impregnated medical devices such as catheters, bone and cardiac implants have been in use for over a decade.[22,38] Various studies have shown the potential of such an approach, for example, in vascular surgery and arthroplasty, where they appear effective in reducing the risk of bloodstream infections or in limiting deep wound infections.[39,40] AM is effective in remission of Pseudomonas keratitis and prevention of cornea perforation and controlling as well as anti-Pseudomonas effects. There was no difference between ciprofloxacin group in comparison with ciprofloxacin + AMT group. However, regarding anti-inflammatory effects, the process of improvement of inflammation in ciprofloxacin + AMT group was faster. During this research, we came to conclusion that transplantation of AM in the primary stages of Pseudomonas keratitis treatment remarkably prevents the disease and it can be used to control its process.

Financial Support and Sponsorship

Nil.

Conflicts of Interest

There are no conflicts of interest.

Acknowledgements

This work was supported by a Vice-Chancellor for Research grant (no. 10793) and approved by the Committee for Research Ethics (no.IR.TUMS.RES.1394.2091) of Tehran University of Medical Sciences (Tehran, Iran).

References

  1. Marino T. Ultrasound abnormalities of the amniotic fluid , membranes , umbilical cord , and placenta. Obs Gynecol Clin North Am. 2004;31:177–200. doi: 10.1016/S0889-8545(03)00125-6. [DOI] [PubMed] [Google Scholar]
  2. Mastropasqua L, Massaro-giordano G, Nubile M, Sacchetti M. doi: 10.1002/jcp.25623. Massaro-giordano G, Nubile M, Sacchetti M. Understanding the pathogenesis of neurotrophic keratitis: the role of corneal nerves. Cell Physiol 2016;September:717–724. [DOI] [PubMed]
  3. Remigio L, Leonidas T. Accelerated collagen cross-linking in the management of advanced Acanthamoeba keratitis. J Arq Bras Oftalmol. 2019;8:103–106. doi: 10.5935/0004-2749.20190018. [DOI] [PubMed] [Google Scholar]
  4. Weng S, Jan R, Chang C, Wang J, Su S. Risk of band keratopathy in patients with end-stage renal disease. Sci Rep. 2016;6:28675. doi: 10.1038/srep28675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Stefan P, Sanziana I, Liliana V, Costin L, Vanessa P, Ciuluvica R. Pseudophakic bullous keratopathy. Rom J Ophthalmol. 2017;61:90–94. doi: 10.22336/rjo.2017.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Tonti E. doi: 10.2147/IMCRJ.S192650. Different graft thicknesses after Descemet stripping endothelial keratoplasty for bullous keratopathy in the two eyes of the same patient. Int Med Case Rep J 2019:55–59. [DOI] [PMC free article] [PubMed]
  7. Mifflin MD, Mortensen XM. Intraoperative optical pachymetry in photorefractive keratectomy. J Cart Refract Surg. 2018;45:495–500. doi: 10.1016/j.jcrs.2018.11.033. [DOI] [PubMed] [Google Scholar]
  8. Ehlke GL, Krueger RR. Laser vision correction in treating myopia. Asia-Pacific J Ophthalmol. 2016;5:434–437. doi: 10.1097/APO.0000000000000237. [DOI] [PubMed] [Google Scholar]
  9. Palamar M, Yaman B, Akalin T, Yagci A. Amniotic membrane transplantation in surgical treatment of conjunctival melanoma: long-term results. Turkish J Ophthalmol. 2018;48:15–18. doi: 10.4274/tjo.62681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Asoklis RS, Damijonaityte A, Butkiene L, Makselis A, Petroska D, Pajaujis M, et al. Ocular surface reconstruction using amniotic membrane following excision of conjunctival and limbal tumors. Eur J Ophthalmol. 2011;21:552–558. doi: 10.5301/EJO.2010.6192. [DOI] [PubMed] [Google Scholar]
  11. Kaufman SC, Jacobs DS, Lee WB, Deng SX, Rosenblatt MI, Shtein RM. Options and adjuvants in surgery for pterygium. Ophthalmology. 2013;120:201–208. doi: 10.1016/j.ophtha.2012.06.066. [DOI] [PubMed] [Google Scholar]
  12. Mitomycin C. Comparison of three methods for the treatment of pterygium: amniotic membrane graft, conjunctival autograft and conjunctival autograft plus. Int J Orbital Disord Oculoplastic Lacrimal Surg. 2007;26:5–13. doi: 10.1080/01676830600972724. [DOI] [PubMed] [Google Scholar]
  13. Gündüz K, Uçakhan OO, Kanpolat A, Günalp I. Nonpreserved human amniotic membrane transplantation for conjunctival reconstruction after excision of extensive ocular surface neoplasia. Eye. 2006;20:351–357. doi: 10.1038/sj.eye.6701890. [DOI] [PubMed] [Google Scholar]
  14. Grewal DS, Mahmoud TH. Dehydrated allogenic human amniotic membrane graft for conjunctival surface reconstruction following removal of exposed scleral buckle. Ophthalmic Surg Lasers Imaging Retina. 2016;47:948–951. doi: 10.3928/23258160-20161004-08. [DOI] [PubMed] [Google Scholar]
  15. Tamhane A, Vajpayee RB, Biswas NR. Evaluation of amniotic membrane transplantation as an adjunct to medical therapy as compared with medical therapy alone in acute ocular burns. Ophthalmology. 2005;112:1963–1969. doi: 10.1016/j.ophtha.2005.05.022. [DOI] [PubMed] [Google Scholar]
  16. Pereira Gomes JA, dos Santos MS, Cunha MC, Mascaro VLD, de Nadai Barros J, Barbosa de Sousa L. Amniotic membrane transplantation for partial and total limbal stem cell deficiency secondary to chemical burn. Ophthalmology. 2003;110:466–473. doi: 10.1016/s0161-6420(02)01888-2. [DOI] [PubMed] [Google Scholar]
  17. Torabi T, Abroun S. Amniotic fluid, an effective factor for umbilical cord blood hematopoietic stem cells in cell culture: an approach for bone marrow transplantation. Transfus Apher Sci. 2019;58:169–173. doi: 10.1016/j.transci.2019.01.001. [DOI] [PubMed] [Google Scholar]
  18. Tejwani S, Kolari RS, Sangwan VS, Rao GN. Role of amniotic membrane graft for ocular chemical and thermal injuries. Cornea. 2007;26:21–26. doi: 10.1097/ICO.0b013e31802b4201. [DOI] [PubMed] [Google Scholar]
  19. Nubile M, Carpineto P, Lanzini M, Ciancaglini M, Zuppardi E, Mastropasqua L. Multilayer amniotic membrane transplantation for bacterial keratitis with corneal perforation after hyperopic photorefractive keratectomy: case report and literature review. J Cataract Refract Surg. 2007;33:1636–1640. doi: 10.1016/j.jcrs.2007.04.040. [DOI] [PubMed] [Google Scholar]
  20. Gicquel J, Bejjani RA, Ellies P. Amniotic membrane transplantation in severe bacterial keratitis. Cornea. 2007;26:27–33. doi: 10.1097/ICO.0b013e31802b28df. [DOI] [PubMed] [Google Scholar]
  21. Heidarzadeh S, Ghasemian A, Kalafi Z, Nikkhahi F, Soltan MM. Antimicrobial effects of amniotic membrane on some bacterial strains. Immunopathol Persa. 2018;4:1–5. [Google Scholar]
  22. Mehdi M, Soltan-Dallal M, Nikkhahi F, Molaei S, Hosseini K, Kazem M, et al. Effect of Amniotic membrane combined with ciprofloxacin in curing the primary stages of pseudomonal keratit. J Med Bacteriol. 2012;1:31–37. [Google Scholar]
  23. Kim HK, Park HS. Fibrin glue-assisted augmented amniotic membrane transplantation for the treatment of large noninfectious corneal perforations. Cornea. 2009;28:170–176. doi: 10.1097/ICO.0b013e3181861c54. [DOI] [PubMed] [Google Scholar]
  24. Chen HC, Tan HY, Hsiao CH, Huang SCM, Lin KK, Ma DHK. Amniotic membrane transplantation for persistent corneal ulcers and perforations in acute fungal keratitis. Cornea. 2006;25:564–572. doi: 10.1097/01.ico.0000227885.19124.6f. [DOI] [PubMed] [Google Scholar]
  25. Kim SJ, Song CH, Sung HJ, Yoo YD, Geum DH, Park SH, et al. Human placenta-derived feeders support prolonged undifferentiated propagation of a human embryonic stem cell line, SNUhES3: comparison with human bone marrow-derived feeders. Stem Cells Dev. 2007;16:421–428. doi: 10.1089/scd.2006.0098. [DOI] [PubMed] [Google Scholar]
  26. Miller DD, Simmons NL, Stewart MW. Recurrent corneal erosion: a comprehensive review. Clin Ophthalmol. 2019;13:325–335. doi: 10.2147/OPTH.S157430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Bouchard CS, John T. Amniotic membrane transplantation in the management of severe ocular surface disease: indications and outcomes. Ocul Surf. 2004;2:201–211. doi: 10.1016/s1542-0124(12)70062-9. [DOI] [PubMed] [Google Scholar]
  28. Dua HS, Gomes JAP, King AJ, Maharajan VS. The amniotic membrane in ophthalmology. Diagnostic Surg Tech. 2004;49:51–77. doi: 10.1016/j.survophthal.2003.10.004. [DOI] [PubMed] [Google Scholar]
  29. Dogan C, Sevki O, Akif A, Burak O. Efficacy of fixation of the amniotic membrane on a symblepharon ring with continuous suturing in acute ocular chemical burn patients. Int Ophthalmol. 2019;39:2103–2109. doi: 10.1007/s10792-018-1049-1. [DOI] [PubMed] [Google Scholar]
  30. Hanada K, Shimazaki J, Shimmura S, Tsubota K. Multilayered amniotic membrane transplantation for severe ulceration of the cornea and sclera. Am J Ophthalmol. 2001;131:324–331. doi: 10.1016/s0002-9394(00)00825-4. [DOI] [PubMed] [Google Scholar]
  31. Jeoung J, Yoon Y, Lee J. The effect of amniotic membrane transplantation on the treatment of necrotizing scleritis after pterygium excision. J Korean Ophthalmol Soc. 2004;45:1981–1988. [Google Scholar]
  32. Azuara-blanco A, Pillai CT, Dua HS. Amniotic membrane transplantation for ocular surface reconstruction. Br J Ophthalmol. 1999;83:399–402. doi: 10.1136/bjo.83.4.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Sangwan VS, Burman S, Tejwani S, Mahesh SP, Murthy R. Amniotic membrane transplantation: a review of current indications in the management of ophthalmic disorders. Indian J Ophthalmol. 2007;55:251–260. doi: 10.4103/0301-4738.33036. [DOI] [PubMed] [Google Scholar]
  34. Niknejad H, Peirovi H, Jorjani M, Ahmadiani A, Ghanavi J, Seifalian M, et al. Properties of the amniotic membrane for potential use in tissue engineering. Eur Cells Mater. 2008;15:88–99. doi: 10.22203/ecm.v015a07. [DOI] [PubMed] [Google Scholar]
  35. King AE, Paltoo A, Kelly RW, Sallenave J, Bocking AD, Challis JRG. Expression of natural antimicrobials by human placenta and fetal membranes. Placenta. 2007;28:161–169. doi: 10.1016/j.placenta.2006.01.006. [DOI] [PubMed] [Google Scholar]
  36. Nguyen Lunde N, Haugland M, Broe K, Larsen B, Damgaard I, Pettersen SJ, et al. Glycosylation is important for legumain localization and processing to active forms but not for cystatin E/M inhibitory functions. Biochimie. 2017;139:27–37. doi: 10.1016/j.biochi.2017.05.009. [DOI] [PubMed] [Google Scholar]
  37. Soltan-dallal MM, Kalafi Z, Rastegar-lari A, Hosseini SK, Rahimi-foroushani A. The effect of reduced bacterial dilution on human amniotic membrane antibacterial activity, in vitro. Zahedan J Res Med Sci. 2013;15:6–8. [Google Scholar]
  38. Quarello F, Forneris G, Borca M, Pozzato M. Do central venous catheters have advantages over arteriovenous fistulas or grafts? J Nephrol 2006;19:265–279. [PubMed]
  39. Kowalewski M, Pawliszak W, Zaborowska K, Navarese EP, Szwed A. Gentamicin-collagen sponge reduces the risk of sternal wound infections after heart surgery: meta-analysis. J Thorac Cardiovasc Surg. 2015;149:1631–1640. doi: 10.1016/j.jtcvs.2015.01.034. [DOI] [PubMed] [Google Scholar]
  40. Harron K, Mok Q, Hughes D, Muller-pebody B, Parslow R. Generalisability and cost-impact of antibiotic-impregnated central venous catheters for reducing risk of bloodstream infection in paediatric intensive care units. PLoS One. 2016;11:e0151348. doi: 10.1371/journal.pone.0151348. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Ophthalmic & Vision Research are provided here courtesy of Ophthalmic Research Center

RESOURCES